Dual inhibition of Akt and c‐Met as a second‐line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells

Sorafenib displays a limited efficacy for advanced hepatocellular carcinoma (HCC). Some patients with HCC initially respond to sorafenib, but eventually succumb to the disease, indicating that the acquired resistance to sorafenib reduces its beneficial effects. No alternative drugs are available aft...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Oncol
Main Authors: Han, Peng, Li, Hali, Jiang, Xian, Zhai, Bo, Tan, Gang, Zhao, Dali, Qiao, Haiquan, Liu, Bing, Jiang, Hongchi, Sun, Xueying
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2017
Assuntos:
Research Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5527443/
https://ncbi.nlm.nih.gov/pubmed/28164434
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/1878-0261.12039
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados